GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmesis International Ltd (SGX:BFK) » Definitions » Shares Buyback Ratio %

Pharmesis International (SGX:BFK) Shares Buyback Ratio % : -14.86 (As of May. 14, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Pharmesis International Shares Buyback Ratio %?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Pharmesis International's current shares buyback ratio was -14.86%.

Pharmesis International Shares Buyback Ratio % Historical Data

The historical data trend for Pharmesis International's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmesis International Shares Buyback Ratio % Chart

Pharmesis International Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -20.00 -14.86

Pharmesis International Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -20.00 - -14.86 -

Pharmesis International Shares Buyback Ratio % Calculation

Pharmesis International's Shares Buyback Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2023 ) - Shares Outstanding (EOP) (A: Dec. 2024 )) / Shares Outstanding (EOP) (A: Dec. 2023 )
=(27.600 - 31.700) / 27.600
=-14.86%

Pharmesis International's Shares Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jun. 2024 ) - Shares Outstanding (EOP) (A: Dec. 2024 )) / Shares Outstanding (EOP) (A: Jun. 2024 )
=(31.700 - 31.700) / 31.700
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmesis International Shares Buyback Ratio % Related Terms

Thank you for viewing the detailed overview of Pharmesis International's Shares Buyback Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmesis International Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmesis International Ltd (SGX:BFK) » Definitions » Shares Buyback Ratio %
Comparable Companies
SGX:42C ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA SHSE:688506 BOM:500087 TSE:4507 SZSE:000538 UTHR NSE:TORNTPHARM BOM:543904 BOM:500124 BOM:500257
Traded in Other Exchanges
N/A
Address
5 Kallang Sector, No. 03-02, Singapore, SGP, 349279
Website
https://www.pharmesis.com
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution. The company derives revenue from the sale of medicines to domestic customers in China.